CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash from Financing Activities across 12 years of filings, most recently posting $591.9 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $591.9 million, up 5490.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 2649.46% YoY), and the FY2025 annual result was $426.0 million, up 28.33% from the prior year.
• Cash from Financing Activities came in at $591.9 million for Q1 2026 at CRISPR Therapeutics AG, up from $116.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $591.9 million in Q1 2026 to a low of -$466000.0 in Q2 2024.
• The 5-year median for Cash from Financing Activities is $10.6 million (2022), against an average of $85.4 million.
• Peak annual rise in Cash from Financing Activities reached 5561.25% in 2024, while the deepest fall reached 102.78% in 2024.
• CRISPR Therapeutics AG's Cash from Financing Activities stood at $2.5 million in 2022, then surged by 1471.39% to $38.9 million in 2023, then plunged by 56.66% to $16.9 million in 2024, then jumped by 589.82% to $116.4 million in 2025, then jumped by 408.45% to $591.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $591.9 million (Q1 2026), $116.4 million (Q4 2025), and $296.8 million (Q3 2025), per Business Quant data.